{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:58:11Z","timestamp":1791845891541,"version":"4.3.4"},"reference-count":25,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jdiacomp.2025.109148","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:11:39Z","timestamp":1754439099000},"page":"109148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Semaglutide and the retina: Weighing evidence against concern"],"prefix":"10.1016","volume":"39","author":[{"given":"Emir","family":"Muzurovi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ksenija","family":"Ze\u010devi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Maggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"El Tanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfredi","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2025.109148_bb0005","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s13300-024-01615-5","article-title":"Modern management of cardiometabolic continuum: from overweight\/obesity to prediabetes\/type 2 diabetes mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group","volume":"15","author":"Janez","year":"2024","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jdiacomp.2025.109148_bb0010","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijcard.2022.07.017","article-title":"Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group","volume":"365","author":"Janez","year":"2022","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jdiacomp.2025.109148_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2024.108931","article-title":"The association between age at diagnosis of diabetes and development of diabetic retinopathy and assessment of healthcare access as an effect modifier","volume":"39","author":"George","year":"2025","journal-title":"J Diabetes Complicat"},{"key":"10.1016\/j.jdiacomp.2025.109148_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2023.108647","article-title":"GLP-1 and dual GIP\/GLP-1 receptor agonists in overweight\/obese patients for atherosclerotic cardiovascular disease prevention: Where are we now?","volume":"37","author":"Muzurovi\u0107","year":"2023","journal-title":"J Diabetes Complicat"},{"key":"10.1016\/j.jdiacomp.2025.109148_bb0025","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2025.109148_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2025.109039","article-title":"Semaglutide, central retinal thickness and continuous glucose monitoring in persons with type 2 diabetes: a post-hoc analysis from a randomised trial","volume":"39","author":"Gullaksen","year":"2025","journal-title":"J Diabetes Complicat"},{"key":"10.1016\/j.jdiacomp.2025.109148_bb0035","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12902-017-0213-3","article-title":"Mechanism of worsening diabetic retinopathy with rapid lowering of blood glucose: the synergistic hypothesis","volume":"17","author":"Jingi","year":"2017","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.jdiacomp.2025.109148_bb0040","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/archopht.116.7.874","article-title":"Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial","volume":"116","year":"1998","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jdiacomp.2025.109148_bb0045","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00592-017-1031-9","article-title":"Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"54","author":"Dicembrini","year":"2017","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.jdiacomp.2025.109148_bb0050","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1080\/14656566.2017.1342810","article-title":"GLP-1 receptor agonists, carotid atherosclerosis and retinopathy","volume":"18","author":"Rizzo","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jdiacomp.2025.109148_bb0055","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3109\/02713683.2010.521968","article-title":"The influence of glucose concentration and hypoxia on VEGF secretion by cultured retinal cells","volume":"36","author":"Kennedy","year":"2011","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.jdiacomp.2025.109148_bb0060","article-title":"Glucagon-like peptide 1 receptor agonists, diabetic retinopathy and angiogenesis: the angiosafe type 2 diabetes study","volume":"105(4):dgz069","author":"Gaborit","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2025.109148_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.endmts.2024.100168","article-title":"Long-term use of semaglutide and risk of diabetic retinopathy progression","volume":"15","author":"Stevens","year":"2024","journal-title":"Endocr Metab Sci"},{"key":"10.1016\/j.jdiacomp.2025.109148_bb0070","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2025.109148_bb0075","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized","volume":"103","author":"Rodbard","year":"2018","journal-title":"controlled trial J Clin Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2025.109148_bb0080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00125-017-4435-8","article-title":"Diabetic retinopathy: hyperglycaemia, oxidative stress and beyond","volume":"61","author":"Hammes","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2025.109148_bb0085","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s13167-023-00314-8","article-title":"Diabetic retinopathy as the leading cause of blindness and early predictor of cascading complications\u2014risks and mitigation","volume":"14","author":"Kropp","year":"2023","journal-title":"EPMA J"},{"key":"10.1016\/j.jdiacomp.2025.109148_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111976","article-title":"HIF-1\u03b1 accumulation in response to transient hypoglycemia may worsen diabetic eye disease","volume":"42","author":"Guo","year":"2023","journal-title":"Cell Rep"},{"key":"10.1016\/j.jdiacomp.2025.109148_bb0095","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jdiacomp.2025.109148_bb0100","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ophtha.2024.10.030","article-title":"Association between semaglutide and nonarteritic anterior ischemic optic neuropathy: a multinational population-based study","volume":"132","author":"Chou","year":"2025","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jdiacomp.2025.109148_bb0105","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3390\/vision7040072","article-title":"Non-arteritic anterior ischemic optic neuropathy (NA-AION): a comprehensive overview","volume":"7","author":"Salvetat","year":"2023","journal-title":"Vision"},{"key":"10.1016\/j.jdiacomp.2025.109148_bb0110","first-page":"1754","article-title":"The prevention opportunities of retinopathy in diabetic patients - position paper endorsed by the Polish Lipid Association","volume":"20","author":"Banach","year":"2024","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.jdiacomp.2025.109148_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2023.108471","article-title":"Association between high-density lipoprotein cholesterol to apolipoprotein A ratio and diabetic retinopathy: a cross-sectional study","volume":"37","author":"Zhang","year":"2023","journal-title":"J Diabetes Complicat"},{"key":"10.1016\/j.jdiacomp.2025.109148_bb0120","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s12933-022-01684-5","article-title":"Personalized management of dyslipidemias in patients with diabetes-it is time for a new approach (2022)","volume":"21","author":"Banach","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2025.109148_bb0125","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1111\/dom.15081","article-title":"Semaglutide reduces the risk of major adverse cardiovascular events consistently across baseline triglyceride levels in patients with type 2 diabetes: Post hoc analyses of the SUSTAIN 6 and PIONEER 6 trials","volume":"25","author":"Verma","year":"2023","journal-title":"Diabetes Obes Metab"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872725002016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872725002016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T15:59:31Z","timestamp":1760803171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872725002016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1056872725002016"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109148","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Semaglutide and the retina: Weighing evidence against concern","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109148","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109148"}}